Phase 3
Completed N=147
SSRI and Buprenorphine
Opiate Dependence · Depression
Source: ClinicalTrials.gov NCT00475878 ↗
Enrolled (actual)
147
Serious AEs
0.7%
Results posted
Apr 2012
Primary outcomePrimary: Percentage of Participants Who Dropped Out of Buprenorphine Treatment — 33.3; 44.0 percentage of participants — p=.19
Summary
This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Who Dropped Out of Buprenorphine Treatment |
33.3; 44.0 | .19 |
| SECONDARY Depressive Symptoms |
12.31; 11.35 | .18 |
Eligibility Criteria
Inclusion Criteria
- opiate dependence
- Ham-D > 14
Exclusion Criteria
- no psychiatric contraindications to using escitalopram
- no medical contraindications to using escitalopram
- methadone dose < 30
- no current SSRI use
Data sourced from ClinicalTrials.gov (NCT00475878). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.